• Events
    • EURETINA 2024 Barcelona
      • Programme Submission Terms
      • Submit Programme Abstract
    • EURETINA 2023 Amsterdam
      • Amsterdam On Demand
      • Congress Daily
      • Congress Photo Gallery
      • Information
      • Programme
      • Abstracts
      • Late Breaking
      • Hotels
      • Registration
      • Exhibition Bookings
      • EURETINA Innovation Spotlight (EIS)
    • EURETINA Innovation Spotlight (EIS)
      • Information
      • Programme
      • Contributors
      • Registration
      • Sponsorship
      • Industry Abstracts
    • EURETINA 2023 Vilnius (Winter Meeting)
      • Information
      • Programme
      • Hotels
      • Exhibition Information
      • Abstract Viewer
    • EURETINA 2022 Hamburg
      • On Demand
      • Sustainability Plan
      • Programme Overview
      • Satellite Symposia
      • Exhibitors
      • Abstract Viewer
    • Future Meetings
    • Upcoming Digital Events
  • Free Resources
    • Webinars
    • Podcasts
    • Case Club Cases
    • Abstract Viewer
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Committees
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • EBO-Euretina Exam
    • Mentorship Programme
    • RMCR Grant Programme
    • Observership Grant Programme
    • Women in Retina
      • Seeing is Believing Collection
    • YOURS
    • CME Credits
  • Member Login
Menu
  • Events
    • EURETINA 2024 Barcelona
      • Programme Submission Terms
      • Submit Programme Abstract
    • EURETINA 2023 Amsterdam
      • Amsterdam On Demand
      • Congress Daily
      • Congress Photo Gallery
      • Information
      • Programme
      • Abstracts
      • Late Breaking
      • Hotels
      • Registration
      • Exhibition Bookings
      • EURETINA Innovation Spotlight (EIS)
    • EURETINA Innovation Spotlight (EIS)
      • Information
      • Programme
      • Contributors
      • Registration
      • Sponsorship
      • Industry Abstracts
    • EURETINA 2023 Vilnius (Winter Meeting)
      • Information
      • Programme
      • Hotels
      • Exhibition Information
      • Abstract Viewer
    • EURETINA 2022 Hamburg
      • On Demand
      • Sustainability Plan
      • Programme Overview
      • Satellite Symposia
      • Exhibitors
      • Abstract Viewer
    • Future Meetings
    • Upcoming Digital Events
  • Free Resources
    • Webinars
    • Podcasts
    • Case Club Cases
    • Abstract Viewer
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Committees
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • EBO-Euretina Exam
    • Mentorship Programme
    • RMCR Grant Programme
    • Observership Grant Programme
    • Women in Retina
      • Seeing is Believing Collection
    • YOURS
    • CME Credits
  • Member Login
  • July 21, 2022
  • 2022 Abstracts

Real-world outcomes of intravitreal fluocinolone acetonide implant for the treatment of recurrent and persistent diabetic macular edema in Portugal – results from the RIVER study based on baseline visual acuity

Author: Susana Penas

Co-authors: Bernardete Pessoa, Carla Teixeira, Joao Paulo Sousa, Miguel Ruao, Angelina Meireles

Abstract

Purpose: The RIVER study was designed to assess portuguese real-world outcomes of the ILUVIEN® implant (0.190 mg fluocinolone acetonide, FAc) in treating persistent and recurrent diabetic macular edema (DME). This study sub-analysis aimed to compare the functional and safety outcomes based on baseline visual acuity (VA).

Setting/Venue: The RIVER study retrospectively assessed patient data from 5 portuguese centers; it was approved by the Ethics Committees (EC) from all the involved centers and was carried out in collaboration with the Retina Study Group (GER) and designed to audit the patient's electronic medical records (EMR) using the database Retina.PT.

Methods: The RIVER study collected data from 222 eyes of 152 patients with persistent and recurrent DME; data on patients’ records from the last 12 months prior to treatment with the ILUVIEN® implant to > 6 months after its implantation was collected; the mean follow-up time after ILUVIEN® was 22.5 ± 9.0 months Twenty-four eyes were excluded in this sub-analysis due to a missing register on baseline VA. Eyes were divided into three major groups according to their baseline VA score (group A: <50 ETDRS letters (n=84), group B: 50-60 ETDRS letters (n=68) and group C: >60 ETDRS letters (n=46). The effect of the implant on best corrected visual acuity (BCVA), central foveal thickness (CFT) and intraocular pressure (IOP) was compared between groups at similar timelines over 36 months. Statistical analysis was performed using IBM SPSS version 28 and Microsoft Excel software.

Results: Baseline demographic characteristics were similar among the 3 groups except for CFT: 524.7 ± 193.7 µm (A), 457.1 ± 108.0 µm (B) and 414.4 ± 138.4 µm (C), (p<0.01). Mean age was 72.2 ± 8.7, 70.4 ± 8.6 and 71.7 ± 8.9 years in group A, B and C, respectively (p=0.979) and mean duration of DME was 4.6 ± 2.9 (A), 4.8 ± 2.9 (B) and 5.1 ± 2.7 years (C) (p=0.844). Mean baseline BCVA was 31.7 ± 10.7 (A), 54.5 ± 4.3 (B) and 69.6 ± 5.0 (C) (p<0.001). A greater VA gain was observed for groups with lower baseline VA: +13 letters (A) (p<0.001), +8 letters (B) (p<0.001) and was kept the same (70 letters) in group C (p=0.665). A more significant reduction in CFT was also observed for the groups with lower baseline VA: -176.0 µm (A) (p<0.001), -148.3 µm (B) (p<0.001), and -45.6 µm (C) (p=0.049). Group C, including eyes with higher baseline VA experienced a ceiling effect enabling a greater gain, as well as preventing a greater reduction in CFT, as they already presented thinner retinas at baseline. Mean IOP remained stable during follow-up (Δ +0.74 mmHg (A), +0.59 mmHg (B) and +0.45 mmHg(C) (p>0.05).

Conclusions (200 words): This sub-analysis from the RIVER study enhances the long-term effectiveness and safety of the fluocinolone acetonide implant for the treatment of persistent and recurrent DME in routine clinical practice in Portugal, regardless of baseline visual acuity. Patients with better vision at baseline maintained their good vision, close to 70 ETDRS letters, throughout the follow-up period, implying that this implant satisfies the DME treatment goal of maintaining or improving vision as a long-term outcome.

Financial Disclosures: Susana Penas - consultant for Alimera, Bayer, Novartis, Roche
NextNext

Secretariat Address
European Society of Retina Specialists
Ground Floor, The Apex Building 
Blackthorn Road
Sandyford Business Park
Co Dublin, D18 H6K2

Phone:+353 1 2100092
Email: [email protected]

EURETINA 2023 Amsterdam

EURETINA Innovation Spotlight (EIS)

Abstract Viewer

Ophthalmologica

Forum

Opportunities

Memberships

About

Privacy Policy

Contact Us

Newsletter Sign up

By clicking 'Subscribe', you agree to the terms of our Privacy Policy. 
 
 

Follow us

© EURETINA 2023 All rights reserved

  • Events
    • EURETINA 2024 Barcelona
      • Programme Submission Terms
      • Submit Programme Abstract
    • EURETINA 2023 Amsterdam
      • Amsterdam On Demand
      • Congress Daily
      • Congress Photo Gallery
      • Information
      • Programme
      • Abstracts
      • Late Breaking
      • Hotels
      • Registration
      • Exhibition Bookings
      • EURETINA Innovation Spotlight (EIS)
    • EURETINA Innovation Spotlight (EIS)
      • Information
      • Programme
      • Contributors
      • Registration
      • Sponsorship
      • Industry Abstracts
    • EURETINA 2023 Vilnius (Winter Meeting)
      • Information
      • Programme
      • Hotels
      • Exhibition Information
      • Abstract Viewer
    • EURETINA 2022 Hamburg
      • On Demand
      • Sustainability Plan
      • Programme Overview
      • Satellite Symposia
      • Exhibitors
      • Abstract Viewer
    • Future Meetings
    • Upcoming Digital Events
  • Free Resources
    • Webinars
    • Podcasts
    • Case Club Cases
    • Abstract Viewer
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Committees
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • EBO-Euretina Exam
    • Mentorship Programme
    • RMCR Grant Programme
    • Observership Grant Programme
    • Women in Retina
      • Seeing is Believing Collection
    • YOURS
    • CME Credits
  • Member Login